The HIV care cascade in sub‐Saharan Africa: systematic review of published criteria and definitions

C Mugglin, D Kläger, A Gueler… - African Journal of …, 2021 - journals.lww.com
2 METHODS We examined guidance on systematic reviews of observational studies [9, 10]
when planning this review and report our review according to the PRISMA statement [11] …

[PDF][PDF] Treatment as Prevention for HIV Infection: Current Data, Challenges, and Global Perspectives.

JC Yombi, H Mertes - AIDS reviews, 2018 - dial.uclouvain.be
Abstract In 2008, the Swiss National AIDS Commission issued a statement about the safety
of HIV treatment in terms of reduced transmission in serodiscordant couples to reduce …

Impaired gut microbiota-mediated short-chain fatty acid production precedes morbidity and mortality in people with HIV

I Sereti, ML Verburgh, J Gifford, A Lo, A Boyd, E Verheij… - Cell reports, 2023 - cell.com
Antiretroviral therapy (ART) has dramatically lengthened lifespan among people with HIV
(PWH), but this population experiences heightened rates of inflammation-related …

[HTML][HTML] Prevalence, determinants, and impact of suboptimal adherence to HIV medication in 25 countries

P de Los Rios, C Okoli, Y Punekar, B Allan… - Preventive …, 2020 - Elsevier
Modern antiretroviral therapy (ART) has improved the lives of people living with HIV (PLHIV)
but currently requires daily adherence. We assessed prevalence and correlates of …

The urgent need for more potent antiretroviral therapy in low-income countries to achieve UNAIDS 90-90-90 and complete eradication of AIDS by 2030

E Ndashimye, EJ Arts - Infectious Diseases of Poverty, 2019 - mednexus.org
Background: Over 90% of Human Immunodeficiency Virus (HIV) infected individuals will be
on treatment by 2020under UNAIDS 90-90-90 global targets. Under World Health …

Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries

B Akinwunmi, D Buchenberger, J Scherzer… - Sexually transmitted …, 2021 - sti.bmj.com
Objectives A novel long-acting regimen (LAR) of cabotegravir and rilpivirine for HIV
treatment requires dosing every 2 months instead of daily. We assessed what proportion of …

Evolution of comorbidities in people living with HIV between 2004 and 2014: cross-sectional analyses from ANRS CO3 Aquitaine cohort

F Bonnet, F Le Marec, O Leleux, Y Gerard… - BMC Infectious …, 2020 - Springer
Background The objective of the study was to describe the evolution of chronic non-AIDS
related diseases and their risk factors, in patients living with HIV (PLHIV) in the French …

Human immunodeficiency virus continuum of care in 11 European Union countries at the end of 2016 overall and by key population: have we made progress?

G Vourli, T Noori, A Pharris, K Porter… - Clinical Infectious …, 2020 - academic.oup.com
Background High uptake of antiretroviral treatment (ART) is essential to reduce human
immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care …

Awareness, knowledge, use, willingness to use and need of Pre-Exposure Prophylaxis (PrEP) during World Gay Pride 2017

C Iniesta, D Álvarez-del Arco, LM García-Sousa… - PLoS …, 2018 - journals.plos.org
Objective To assess the awareness, knowledge, use, and willingness to use and need of
PrEP among men who have sex with men (MSM) and transgender women (TW) who …

Substantial heterogeneity in progress toward reaching the 90-90-90 HIV target in the WHO European region

K Porter, A Gourlay, K Attawell, D Hales… - JAIDS Journal of …, 2018 - journals.lww.com
Background: Achieving the UNAIDS 90-90-90 target by 2020 is expected to end the HIV
epidemic by 2030. We report on progress in the WHO European Region in meeting this …